Table 2.
Cohort Demographics and Clinical Characteristics
| FIVE | VALOR-PD | AT-HOME PD | |||
| PD (n = 159) | Controls (n = 44) | LRRK2 with PD (n = 60) | LRRK2 without PD (n = 217) | PD (n = 226) | |
| Age, mean (SD) | 66.7 (8.9) | 62.2 (11.7) | 67.8 (8.4) | 53.7 (15.1) | 65.9 (9.4) |
| Non-white, n (%) | 6 (3.9%) | < 5a | < 5a | < 5a | 10 (4.4%) |
| Latino/Hispanic, n (%) | < 5 | < 5 | < 5 | 16 (7.4%) | 6 (2.7%) |
| Male, n (%) | 97 (61.0%) | 22 (50.0%) | 29 (48.3%) | 89 (41.4%) | 136 (60.2%) |
| Education > High School, n (%) | 143 (89.9%) | 42 (94.5%) | 59 (98.3%) | 215 (99.0%) | 213 (94.2%) |
| Montreal Cognitive Assessment, mean (SD) | 25.3 (3.6) | 26.5 (2.7) | 27.1 (2.2) | 27.6 (2.1) | 27.9 (2.0) |
| Modified Hoehn &Yahr stage, median (min-max) | 2 (0–5) | 0 (0–4) | 2 (1–5) | 0 (0–2) | 2 (0–3) |
| Taking levodopa, n (%) | 124 (78.0%) | 3 (6.8%) | 53 (88.3%) | 0 (0.0%) | 195 (86.2%) |
aSelf-reported race was captured but is not reported here given small numbers and concerns regarding confidentiality.